Skip to main content

Table 6 Genotypes of 8 SNPs of FGFR gene and their associations with adverse events

From: Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients

Target Gene

Polymorphisms/Genotype

Toxicity(grade 3–4)

N = 102(48%)

No toxicity (grade1–2)

N = 109(52%)

OR (95%CI)

P

P HWE

FGFR1

rs2288696

    

0.035

 

C/C

85(83.3%)

88(80.7%)

Reference

  
 

C/T

14(13.7%)

19(17.4%)

0.76(0.36—1.62)

0.480

 
 

T/T

3(2.9%)

2(1.8%)

1.55(0.25—9.53)

0.634

 
 

Dominat model

17(16.7%)

21(19.3%)

0.84(0.41—1.70)

0.624

 
 

Recessive model

99(97.1%)

107(98.2%)

0.62(0.10—3.77)

0.601

 
 

Alleles

     
 

C

184(90.2%)

195(89.4%)

Reference

  
 

T

20(9.8%)

23(10.6%)

0.92(0.49—1.73)

0.800

 

FGFR2

rs2981582

    

0.138

 

C/C

52(51.0%)

47(43.1%)

Reference

  
 

C/T

37(36.3%)

47(43.1%)

0.71(0.40—1.28)

0.253

 
 

T/T

13(12.7%)

15(13.8%)

0.78(0.34—1.82)

0.569

 
 

Dominat model

50(49.0%)

62(56.9%)

0.73(0.42—1.25)

0.253

 
 

Recessive model

89(87.3%)

94(86.2%)

1.09(0.49—2.43)

0.828

 
 

Alleles

     
 

C

141(69.1%)

141(64.7%)

Reference

  
 

T

63(30.9%)

77(35.3%)

0.82(0.55—1.30)

0.333

 
 

rs1219648

    

0.726

 

A/A

34(33.3%)

33(30.3%)

Reference

  
 

A/G

49(48.0%)

57(52.3%)

0.83(0.45—1.54)

0.562

 
 

G/G

19(18.6%)

19(17.4%)

0.97(0.44—2.15)

0.941

 
 

Dominat model

68(66.7%)

76(69.7%)

0.87(0.49—1.55)

0.634

 
 

Recessive model

83(81.4%)

90(82.6%)

0.92(0.46—1.86)

0.821

 
 

Alleles

     
 

A

117(57.4%)

123(56.4%)

Reference

  
 

G

87(42.6%)

95(43.6%)

0.96(0.66—1.42)

0.847

 
 

rs2420946

    

0.172

 

T/T

13(12.7%)

22(20.2%)

Reference

  
 

C/T

39(38.2%)

51(46.8%)

1.29(0.58—2.89)

0.529

 
 

C/C

50(49.0%)

36(33.0%)

2.35(1.05—5.28)

0.038*

 
 

Dominat model

89(87.3%)

87(79.8%)

1.73(0.82—3.65)

0.150

 
 

Recessive model

52(51.0%)

73(67.0%)

0.51(0.29—0.90)

0.019*

 
 

Alleles

     
 

T

65(31.9%)

95(43.6%)

Reference

  
 

C

139(68.1%)

123(56.4%)

1.65(1.11—2.46)

0.013*

 
 

rs2981579

    

0.196

 

T/T

29(28.4%)

25(22.9%)

Reference

  
 

C/T

38(37.3%)

58(53.2%)

0.57(0.29—1.11)

0.096

 
 

C/C

35(34.3%)

26(23.9%)

1.16(0.56—2.43)

0.692

 
 

Dominant model

73(71.6%)

84(77.1%)

0.75(0.40—1.39)

0.361

 
 

Recessive model

67(65.7%)

83(76.1%)

0.60(0.33—1.09)

0.095

 
 

Alleles

     
 

T

96(47.1%)

108(49.5%)

Reference

  
 

C

108(52.9%)

110(50.5%)

1.11(0.75—1.62)

0.610

 
 

rs2981578

    

0.909

 

G/G

30(29.4%)

70(64.2%)

Reference

  
 

A/G

61(59.8%)

29(26.6)

4.91(2.65—9.08)

< 0.0001*

 
 

A/A

11(10.8%)

10(9.1%)

2.57(0.99—6.69)

0.054

 
 

Dominant model

72(70.6%)

39(35.8%)

2.57(0.99–6.69)

< 0.0001*

 
 

Recessive model

91(89.2%)

99(90.8%)

0.84(0.34–2.06)

0.697

 
 

Alleles

     
 

G

121(59.3%)

169(82.8%)

Reference

  
 

A

83(40.7%)

49(24.0%)

2.37(1.55—3.61)

< 0.0001*

 

FGFR3

rs743682

    

0.682

 

G/G

85(83.3%)

92(84.4%)

Reference

  
 

A/G

15(14.7%)

17(15.6%)

0.96(0.45—2.03)

0.955

 
 

A/A

2(2.0%)

0

0.00

0.999

 
 

Dominant model

17(16.7%)

17(15.6%)

1.08(0.52—2.26)

0.833

 
 

Recessive model

100(98.0%)

109(100.0%)

0.00

0.999

 
 

Alleles

     
 

G

185(90.7%)

201(92.2%)

Reference

  
 

A

19(9.3%)

17(7.8%)

1.21(0.61—2.41)

0.578

 

FGFR4

rs1966265

    

0.998

 

G/G

22(21.6%)

19(17.4%)

Reference

  
 

A/G

46(45.1%)

58(53.2%)

0.69(0.33—1.42)

0.307

 
 

A/A

34(33.3%)

32(29.4%)

0.92(0.42—2.00)

0.829

 
 

Dominant model

80(78.4%)

90(82.6%)

0.77(0.39—1.52)

0.449

 
 

Recessive model

68(66.7%)

77(70.6%)

0.83(0.46—1.49)

0.534

 
 

Alleles

     
 

G

90(44.1%)

96(44. %)

Reference

  
 

A

114(55.9%)

122(56.0%)

1.00(0.68—1.46)

0.987

 
  1. OR odds ratio, 95% CI 95% confidence interval, * A P value < 0.05 was considered ststistically significant
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us